Patents Assigned to Cytel Corporation
-
Publication number: 20030143567Abstract: This invention provides methods for practical enzymatic conversion of GDP-mannose to GDP-fucose. These methods are useful for efficient synthesis of reactants used in the synthesis of fucosylated oligosaccharides.Type: ApplicationFiled: July 25, 2002Publication date: July 31, 2003Applicant: Cytel CorporationInventor: Eric R. Sjoberg
-
Publication number: 20030134403Abstract: This invention provides methods for practical enzymatic conversion of GDP-mannose to GDP-fucose. These methods are useful for efficient synthesis of reactants used in the synthesis of fucosylated oligosaccharides.Type: ApplicationFiled: July 25, 2002Publication date: July 17, 2003Applicant: Cytel CorporationInventor: Eric R. Sjoberg
-
Publication number: 20030013636Abstract: The invention provides methods for inhibiting immune responses by inhibiting the biosynthesis of the sialyl galactosides that are involved in immune responses. In particular, B lymphocyte-mediated immune responses are mediated by interfering with synthesis of &agr;2,6 sialylgalactosides, while T lymphocyte-mediated immune responses are inhibited by blocking synthesis of &agr;2,3 sialylgalactosides. The inhibition is accomplished by, for example, inhibiting the activity of a glycosyltransferase involved in synthesis of the respective sialyl galactoside.Type: ApplicationFiled: April 23, 2002Publication date: January 16, 2003Applicant: Cytel CorporationInventors: Jamey D. Marth, James C. Paulson
-
Publication number: 20020119516Abstract: This invention provides methods for practical in vitro sialylation of glycoproteins, including recombinantly produced glycoproteins. The methods are useful for large-scale modification of sialylation patterns.Type: ApplicationFiled: November 9, 2001Publication date: August 29, 2002Applicant: Cytel CorporationInventors: James C. Paulson, Robert J. Bayer, Eric Sjoberg
-
Patent number: 6156316Abstract: Fusion-point spanning peptides, for example BCR-ABL fusion breakpoint peptides associated with chronic myelogenous leukemia (CML), bind major histompatibility complex molecules, such as HLA class I molecules, and induce cytotoxic T cell proliferation. The breakpoint peptides can be used as vaccines.Type: GrantFiled: May 8, 1995Date of Patent: December 5, 2000Assignees: Sloan-Kettering Institute for Cancer Research, Cytel CorporationInventors: David A. Scheinberg, Alessandro Sette, Monica Bocchia
-
Patent number: 6117840Abstract: The present invention contemplates a peptide that inhibits the binding between the VLA-4 receptor expressed on inflammatory leukocytes and the fibronectin CS-1 peptide expressed on endothelial cells that are involved in immunoinflammatory disease states. Pharmaceutical compositions containing a contemplated peptide and processes for treating immunoinflammatory conditions using a binding-inhibitory peptide are also disclosed.Type: GrantFiled: April 14, 1997Date of Patent: September 12, 2000Assignee: Cytel CorporationInventors: Thomas S. Arrhenius, Mariano J. Elices, Federico C. A. Gaeta
-
Patent number: 6103870Abstract: The present invention contemplates a peptide that inhibits the binding between the VLA-4 receptor expressed on inflammatory leukocytes and the fibronectin CS-1 peptide expressed on endothelial cells that are involved in immunoinflammatory disease states. Pharmaceutical compositions containing a contemplated peptide and processes for treating immunoinflammatory conditions using a binding-inhibitory peptide are also disclosed.Type: GrantFiled: September 3, 1997Date of Patent: August 15, 2000Assignee: Cytel CorporationInventors: Thomas S. Arrhenius, Mariano J. Elices, Federico C. A. Gaeta
-
Patent number: 6033667Abstract: The present invention relates to compositions and methods for treating inflammation and other pathological conditions using novel blocking P-selectin antibodies that inhibit adhesion of leukocytes to activated platelets and/or to activated vascular endothelium in vivo. Both murine and humanized antibodies are provided.Type: GrantFiled: November 5, 1997Date of Patent: March 7, 2000Assignee: Cytel CorporationInventors: Robert W. Chesnut, Margaret J. Polley, James C. Paulson, S. Tarran Jones, Jose W. Saldanha, Mary M. Bendig, Michael Kriegler, Carl Perez, Robert Bayer, Michael Nunn
-
Patent number: 5936065Abstract: The present invention contemplates a compound defined by the following formula: ##STR1## that inhibits the binding between the VLA-4 and the fibronectin CS-1 compound. Pharmaceutical compositions containing a contemplated compound and methods for treating immunoinflammatory conditions using the compound are also disclosed.Type: GrantFiled: June 5, 1995Date of Patent: August 10, 1999Assignee: Cytel CorporationInventors: Thomas S. Arrhenius, Mariano J. Elices, Federico C. A. Gaeta
-
Patent number: 5922577Abstract: The present invention provides improved methods for the formation of glycosidic linkages. These methods are useful for the preparation of compounds of formula:NeuAc.alpha.(2.fwdarw.3)Gal.beta.(1.fwdarw.4)(Fuc.alpha. 1.fwdarw.3)GlcN(R').beta.(1.fwdarw.3)Gal.beta.Type: GrantFiled: April 10, 1996Date of Patent: July 13, 1999Assignee: Cytel CorporationInventors: Shawn Defrees, Robert J. Bayer, Murray Ratcliffe
-
Patent number: 5876980Abstract: The present invention provides improved methods for the preparation of sialyl galactosides. The methods use sialyl transferase cycle in which the reaction conditions are optimized to provide increased yields.Type: GrantFiled: April 11, 1995Date of Patent: March 2, 1999Assignee: Cytel CorporationInventors: Shawn DeFrees, Robert J. Bayer, Murray Ratcliffe
-
Patent number: 5869448Abstract: The present invention contemplates a cyclic peptide that inhibits the binding between the VLA-4 receptor expressed on inflammatory leukocytes and the fibronectin CS-1 peptide expressed on endothelial cells that are involved in immunoinflammatory disease states. Pharmaceutical compositions containing a contemplated cyclic peptide and processes for treating immunoinflammatory conditions using a binding-inhibitory cyclic peptide are also disclosed.Type: GrantFiled: August 25, 1995Date of Patent: February 9, 1999Assignee: Cytel CorporationInventors: Thomas S. Arrhenius, Anna Tempczyk, Mariano J. Elices, Zhong-Li Zheng
-
Patent number: 5856159Abstract: A gene expression system for producing galactosyltransferase comprises an NSO cell recombinantly modified with a polynucleotide encoding galactosyltransferase or a portion thereof which catalyzes the reaction:UDP-D-galactose+N-acetylglucosamine.fwdarw.UDP+D-galactosyl-N-acetyl-D-gluc osamineFurther provided is a method for producing galactosyltransferase by culturing the gene expression system.Type: GrantFiled: March 27, 1996Date of Patent: January 5, 1999Assignee: Cytel CorporationInventor: Carl Perez
-
Patent number: 5854218Abstract: The present invention relates to analogues of sialyl Le.sup.x that inhibit cellular adhesion between a selectin and cells that express sialyl Le.sup.x on their surfaces, as well as methods and compositions using the same, intermediates and methods for the preparation of the cellular adhesion inhibitor compounds and their intermediates.Type: GrantFiled: October 15, 1996Date of Patent: December 29, 1998Assignee: Cytel CorporationInventor: Shawn A. DeFrees
-
Patent number: 5846827Abstract: Methods for activating cytotoxic T lymphocytes (CTL) in vitro are presented in conjunction with methods for using the activated CTL for therapy in vivo. Additionally, a method for killing specific CTL in vivo is presented using antigen presenting cells which were modified in vitro.Type: GrantFiled: June 6, 1995Date of Patent: December 8, 1998Assignee: Cytel CorporationInventors: Esteban Celis, Ralph Kubo, Horacio Serra, Van Tsai, Peggy Wentworth
-
Patent number: 5821231Abstract: The present invention contemplates a compound defined by the following formula: ##STR1## that inhibits the binding between the VLA-4 and the fibronectin CS-1 compound. Pharmaceutical compositions containing a contemplated compound and methods for treating immunoinflammatory conditions using the compound are also disclosed.Type: GrantFiled: June 5, 1995Date of Patent: October 13, 1998Assignee: Cytel CorporationInventors: Thomas S. Arrhenius, Mariano J. Elices, Federico C. A. Gaeta
-
Patent number: 5811404Abstract: The present invention relates to analogues of sialyl Le.sup.x the inhibit cellular adhesion between a selectin and cell that express sialyl Le.sup.x on their surfaces, as well as methods and compositions using the same, intermediates and methods for the preparation of the celluar adhesion inhibitor compounds and their intermediates. A contemplated intermediate or inhibitor compound has a structure that corresponds to that of Formula A, ##STR1## wherein: Z is selected from the group consisting of hydrogen, C.sub.1 -C.sub.Type: GrantFiled: June 7, 1995Date of Patent: September 22, 1998Assignee: Cytel CorporationInventors: Shawn De Frees, Federico C. A. Gaeta, John J. Gaudino, Zhongli Zheng, Masaji Hayashi
-
Patent number: 5811391Abstract: The present invention contemplates a cyclic peptide that inhibits the binding between the VLA-4 receptor expressed on inflammatory leukocytes and the fibronectin CS-1 peptide expressed on endothelial cells that are involved in immunoinflammatory disease states. Pharmaceutical compositions containing a contemplated cyclic peptide and processes for treating immunoinflammatory conditions using a binding-inhibitory cyclic peptide are also disclosed.Type: GrantFiled: June 7, 1995Date of Patent: September 22, 1998Assignee: Cytel CorporationInventors: Thomas S. Arrhenius, Mariano J. Elices, Anna Tempczyk, Zhong-Li Zheng
-
Patent number: 5800815Abstract: The present invention relates to compositions and methods for treating inflammation and other pathological conditions using novel blocking P-selectin antibodies that inhibit adhesion of leukocytes to activated platelets and/or to activated vascular endothelium in vivo. Both murine and humanized antibodies are provided.Type: GrantFiled: February 25, 1994Date of Patent: September 1, 1998Assignee: Cytel CorporationInventors: Robert W. Chestnut, Margaret J. Polley, James C. Paulson, S. Tarran Jones, Jose W. Saldanha, Mary M. Bendig, Michael Kriegler, Carl Perez, Robert Bayer, Michael Nunn
-
Patent number: 5770573Abstract: The present invention contemplates a compound defined by the following formula: ##STR1## that inhibits the binding between the VLA-4 and the fibronectin CS-1 compound. Pharmaceutical compositions containing a contemplated compound and methods for treating immunoinflammatory conditions using the compound are also disclosed.Type: GrantFiled: June 5, 1995Date of Patent: June 23, 1998Assignee: Cytel CorporationInventors: Thomas S. Arrhenius, Mariano J. Elices, Federico C.A. Gaeta